Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Serum Bactericidal Assay

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

Trial Status

Completed1
Enrolling By Invitation1
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT07292493Enrolling By Invitation

Immune System in Diabetic Kidney Disease

NCT06906692Active Not Recruiting

Meningococcal Vaccination in Patients on Complement Inhibitors

NCT06495151Completed

Endometriosis and Complement System

Showing all 3 trials

Research Network

Common Treatments

  • Serum Bactericidal Assay1
  • Complement Factor H Cfh Level1
  • Cancer Antigen 125 Ca125 Level1
  • Adipsin Level1
  • Mannosebinding Lectinassociated Serine Protease3 Masp3 Level1

Active Sponsors

  • Ankara City Hospital Bilkent1
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS1
  • University Medical Centre Ljubljana1

Top Investigators

Related Conditions

  • Endometriosis1
  • Diabetic Kidney Disease1
  • Alternative Complement Pathway1
  • Diabetes1
  • Myasthenia Gravis Generalised1

Activity Timeline